RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-1.44%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.75B
AUM Growth
+$1.75B
(-33%)
Cap. Flow
-$723M
Cap. Flow
% of AUM
-41.38%
Top 10 Holdings %
Top 10 Hldgs %
36.57%
Holding
113
New
6
Increased
25
Reduced
47
Closed
16
Top Buys
| 1 |
Tarsus Pharmaceuticals
TARS
|
$12.5M |
| 2 |
Danaher
DHR
|
$12.1M |
| 3 |
Evolent Health
EVH
|
$6.02M |
| 4 |
Mineralys Therapeutics
MLYS
|
$5.09M |
| 5 |
Merus
MRUS
|
$3.71M |
Top Sells
| 1 |
Intuitive Surgical
ISRG
|
$56.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
$48.8M |
| 3 |
Freshpet
FRPT
|
$48.5M |
| 4 |
UnitedHealth
UNH
|
$39.5M |
| 5 |
Travere Therapeutics
TVTX
|
$36.8M |
Sector Composition
| 1 | Healthcare | 99.7% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$43.6B
| $104M | 5.95% | 175,750 -53,850 | -23% | -$31.9M |
|
2
Eli Lilly
LLY
$657B
| $93.7M | 5.36% | 113,500 -31,000 | -21% | -$25.6M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $89.2M | 5.1% | 1,007,569 -89,330 | -8% | -$7.91M |
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $55.2M | 3.16% | 166,698 -98,514 | -37% | -$32.6M |
|
|
5
UnitedHealth
UNH
$281B
| $52.6M | 3.01% | 100,500 -75,500 | -43% | -$39.5M |
|
|
6
Travere Therapeutics
TVTX
$1.56B
| $52.3M | 3% | 2,921,196 -2,052,453 | -41% | -$36.8M |
|
|
7
Intuitive Surgical
ISRG
$170B
| $50.5M | 2.89% | 102,000 -114,000 | -53% | -$56.5M |
|
8
Ultragenyx Pharmaceutical
RARE
$2.89B
| $50.5M | 2.89% | 1,394,434 -345,379 | -20% | -$12.5M |
|
9
Penumbra
PEN
$10.6B
| $45.7M | 2.62% | 171,000 -69,000 | -29% | -$18.5M |
|
10
Revolution Medicines
RVMD
$7.1B
| $45.3M | 2.59% | 1,281,640 +68,383 | +6% | +$2.42M |
|
11
Rhythm Pharmaceuticals
RYTM
$6.85B
| $44.2M | 2.53% | 834,188 -328,530 | -28% | -$17.4M |
|
12
Mirum Pharmaceuticals
MIRM
$3.71B
| $42.9M | 2.45% | 951,765 -519,799 | -35% | -$23.4M |
|
|
13
Merus
MRUS
$4.98B
| $41.3M | 2.36% | 980,751 +88,202 | +10% | +$3.71M |
|
14
Insmed
INSM
$28.8B
| $39.4M | 2.25% | 515,900 -34,100 | -6% | -$2.6M |
|
15
Alnylam Pharmaceuticals
ALNY
$58.5B
| $38.7M | 2.21% | 143,250 -112,950 | -44% | -$30.5M |
|
16
Ascendis Pharma
ASND
$11.8B
| $33.7M | 1.93% | 216,000 -89,000 | -29% | -$13.9M |
|
17
Zai Lab
ZLAB
$3.68B
| $32.7M | 1.87% | 904,592 -400,745 | -31% | -$14.5M |
|
18
Xenon Pharmaceuticals
XENE
$2.98B
| $31.3M | 1.79% | 931,681 -320,178 | -26% | -$10.7M |
|
|
19
Neurocrine Biosciences
NBIX
$13.8B
| $30.9M | 1.77% | 279,000 -441,500 | -61% | -$48.8M |
|
20
Nuvalent
NUVL
$5.52B
| $30.3M | 1.73% | 427,532 -2,462 | -0.6% | -$175K |
|
21
Agilon Health
AGL
$530M
| $30.1M | 1.72% | 6,950,000 -513,300 | -7% | -$2.22M |
|
22
Phreesia
PHR
$1.88B
| $29.4M | 1.68% | 1,148,336 -891,664 | -44% | -$22.8M |
|
23
Boston Scientific
BSX
$156B
| $27.9M | 1.6% | 277,000 -183,000 | -40% | -$18.5M |
|
24
Akero Therapeutics
AKRO
$3.74B
| $27.2M | 1.56% | 672,759 -273,740 | -29% | -$11.1M |
|
25
DexCom
DXCM
$29.5B
| $27.2M | 1.55% | 397,650 +44,650 | +13% | +$3.05M |
|